

May 17, 2016

ONO Enters an Agreement with IDAC Theranostics relating to Exclusive Evaluation and License Negotiation on IT1208, anti-CD4 antibody

ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President, Representative Director, Gyo Sagara; “ONO”) announced that it entered into an option agreement with IDAC Theranostics, Inc. (Tokyo, Japan; President, Satoru Ito; “IDAC”) on May 16, 2016, under which ONO is granted a right for exclusive evaluation and license negotiation on IT1208, a humanized anti-CD4 antibody being developed by IDAC.

During the term of such agreement, IDAC will conduct a Phase I study of IT1208 in solid tumors in Japan. IT1208 transiently depletes CD4⁺ T cells and removes an immunosuppressive environment, leading to activation of antitumor immunity mediated mainly by CD8⁺ T cells. In preclinical studies, anti-CD4 antibody has demonstrated a potent antitumor activity in tumor-bearing mice.

About anti CD4 antibody (IT1208)

IT1208 is a humanized anti-CD4 antibody with an enhanced antibody-dependent-cellular-cytotoxicity (ADCC) activity using Potelligent technology from Kyowa Hakko Kirin Co., Ltd.

About ONO PHARMACEUTICAL CO., LTD.

ONO PHARMACEUTICAL CO., LTD, headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas. For more information, please visit the company's website at <http://www.ono.co.jp/eng/index.html>.

About IDAC Theranostics. Inc.

IDAC Theranostics, Inc. was established on April 2, 2012, by Koji Matsushima, Professor of Graduate School of Medicine, The University of Tokyo and others, and it has been developing IT1208, which was licensed from Kyowa Hakko Kirin Co., Ltd. as a drug candidate. For more information, please visit the company's website at <http://www.idac-thera.com>

Contact

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

public_relations@ono.co.jp